GED aPC

Drug Profile

GED aPC

Alternative Names: GED-aPC; LY458202

Latest Information Update: 15 Apr 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Class Anticoagulants; Antithrombotics
  • Mechanism of Action Protein C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Cardiogenic shock

Most Recent Events

  • 23 Nov 2010 Suspended - Phase-I for Cardiogenic shock in Canada (IV)
  • 25 Sep 2009 Cardiome is seeking inverstors and/or partners to fund the development of GED aPC \http://www.cardiome.com/index.php\
  • 24 Mar 2009 Phase-I development is ongoing in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top